The Rebif new formulation story: it's not trials and error.

The Rebif new formulation story: it's not trials and error. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

The Rebif new formulation story: it's not trials and error. Abstract Text:

Amer Jaber,Reinoud Driebergen,Gavin Giovannoni,Huub Schellekens,James Simsarian,Michele Antonelli,Amer Jaber,Reinoud Driebergen,Gavin Giovannoni,Huub Schellekens,James Simsarian,Michele Antonelli,

The rapid evolution of the biopharmaceutical industry and the development of innovative technologies have provided an opportunity to improve recombinant interferon (IFN)-beta formulations. A number of strategies have been developed to improve the stability, tolerability and immunogenicity of IFNbeta formulations that are used in the long-term treatment of patients with multiple sclerosis (MS). This review focuses on the production of recombinant IFNs and discusses the development of one such biopharmaceutical, Rebif New Formulation (RNF).RNF was developed with the aim of further improving the tolerability and immunogenicity of Rebif, an approved IFNbeta-1a formulation administered subcutaneously three times per week (sc tiw).To this end, numerous candidate drug vehicles and formulations were developed. However, unlike other formulations of IFNbeta, the new candidate formulations in this case were free from all serum-derived components. Specifically, each RNF candidate was free from human serum albumin and produced without fetal bovine serum. The physicochemical stability, injection-site tolerability, pharmacokinetic profile and immunogenic potential of each candidate formulation were systematically tested. This involved initial screening of a large pool of formulations for promising candidates. Two candidate formulations were selected and subjected to further, extensive evaluation.Ex vivo T-cell assays were used to compare the immunogenicity of RNF candidates with that of the current (at the time of writing) approved formulation and an IFNbeta standard. A single RNF candidate induced less T-cell activation, in terms of proliferation and proinflammatory cytokine secretion, than the other two formulations. The results provided ex vivo evidence of the improved immunogenic potential of RNF. A murine model was used to compare the relative immunogenicity of RNF in vivo with two approved formulations of IFNbeta-1a. Mice treated with RNF developed neutralising antibodies more slowly and produced lower titres than mice treated with equivalent doses of the current IFNbeta-1a sc tiw formulation or another approved IFNbeta-1a formulation administered intramuscularly once per week (Avonex). RNF also demonstrated better local tolerability than the current IFNbeta-1a sc tiw formulation after single subcutaneous doses in healthy volunteers.One RNF candidate was superior to the others in all preclinical and phase I studies, and was chosen as the final RNF. This formulation is currently undergoing assessment in a 96-week, phase IIIb clinical trial in patients with MS. This single-arm, open-label, multicentre study will compare the immunogenicity and tolerability of RNF with historical data on the current formulation; results of a 48-week, interim analysis indicate that RNF has improved local tolerability and immunogenicity compared with the current formulation. It is anticipated that the benefits of RNF will translate into an improved long-term benefit-to-risk profile. Further assessment of RNF and other MS drugs is ongoing with the aim of enhancing the therapeutic options available for patients with MS.

The Rebif new formulation story: it's not trials and error. Publishing Authors By Initials

A Jaber,R Driebergen,G Giovannoni,H Schellekens,J Simsarian,M Antonelli,A Jaber,R Driebergen,G Giovannoni,H Schellekens,J Simsarian,M Antonelli,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

The Rebif new formulation story: it's not trials and error. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Drugs in R&D

VOLUME: 8

Page Numbers: 335-48

Journal Abbreviation:

ISSN: 1174-5886

DAY: 29

MONTH: 10

YEAR: 2007

The Rebif new formulation story: it's not trials and error. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100883647

The Rebif new formulation story: it's not trials and error. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: The Rebif new formulation story: it's not trials and error. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for The Rebif new formulation story: it's not trials and error.

AFFILIATION: Merck Serono International SA, Geneva, Switzerland (an affiliate of Merck KGaA, Darmstadt, Germany).

Country: New Zealand

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Drugs R D

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

The Rebif new formulation story: it's not trials and error Related Publications

• 1-Hexene Isomerization over Sulfated Mesoporous Ta Oxide: The Effects of Active Site and Confinement.
• Carotid integrated backscatter analysis in patients with subclinical hypothyroidism.
• Changes in heart rate variability and QT dispersion in patients with overt hypothyroidism.
• Crisis in health care.
• Determinants of reduced interferon gamma expression in severe respiratory syncytial virus disease: the authors respond.
• Electric response audiometry in infants and preschool children. Long-term control of the results.
• Enteric glial cells and their role in gastrointestinal motor abnormalities: introducing the neuro-gliopathies.
• Expression levels of MDR1, MRP1, MRP4, and MRP5 in peripheral blood mononuclear cells from HIV infected patients failing antiretroviral therapy.
• Functional hemodynamic monitoring and dynamic indices of fluid responsiveness.
• H2 Storage Materials (22KJ/mol) Using Organometallic Ti Fragments as sigma-H2 Binding Sites.
• Hepatobiliary involvement in adolescents and adults with cystic fibrosis.
• Higher level phylogeny and evolutionary trends in Campanulaceae subfam. Lobelioideae: Molecular signal overshadows morphology.
• Hydrogen storage in mesoporous titanium oxide-alkali fulleride composites.
• Mesolimbic dopamine and cortico-accumbens glutamate afferents as major targets for the regulation of the ventral striato-pallidal GABA pathways by neurotensin peptides.
• Modeling equilibrium concentrations of Bjerrum and molecular point defects and their complexes in ice I(h).
• Noninvasive positive-pressure ventilation with different interfaces in patients with respiratory failure after abdominal surgery: a matched-control study.
• On the trapping of Bjerrum defects in ice Ih: the case of the molecular vacancy.
• Optical underwater acoustic sensor.
• Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study.
• Study of the genotypic resistant pattern in HIV-infected women and children from rural west Cameroon.
• Sulfated and phosphated mesoporous Nb oxide in the benzylation of anisole and toluene by benzyl alcohol.
• Sulfated mesoporous tantalum oxides in the shape selective synthesis of linear alkyl benzene.
• The CK1 gene family: expression patterning in zebrafish development.
• The Rebif new formulation story: it's not trials and error.
• Upregulation of interferon-induced genes in infants with virus-associated acute bronchiolitis.
• [Anginal syndrome caused by lung cancer.]
• [Emotional hyperglycemia caused by hospitalization]
• [Maximum sterno-chondro-epigastrico inspiratory retraction in the terminal stage of multiple myeloma]
• [Rheumatic neuroses; psychosomatic aspects of psychogenic or functional rheumatism.]
• [Ultrasonographic study of renal cystic disease]